{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:22:16Z","timestamp":1790670136519,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["TDI-4258"],"award-info":[{"award-number":["TDI-4258"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["TDI-8304"],"award-info":[{"award-number":["TDI-8304"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI143714"],"award-info":[{"award-number":["R01 AI143714"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21\/R33 AI125781"],"award-info":[{"award-number":["R21\/R33 AI125781"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI109023"],"award-info":[{"award-number":["R01 AI109023"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI133393"],"award-info":[{"award-number":["R21 AI133393"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI146387"],"award-info":[{"award-number":["R21 AI146387"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI158612"],"award-info":[{"award-number":["R01 AI158612"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007231","name":"Cornell University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210520"],"award-info":[{"award-number":["W81XWH2210520"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210015"],"award-info":[{"award-number":["W81XWH2210015"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1162467"],"award-info":[{"award-number":["OPP1162467"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-037899"],"award-info":[{"award-number":["INV-037899"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.chembiol.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T10:45:29Z","timestamp":1679568329000},"page":"470-485.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome"],"prefix":"10.1016","volume":"30","author":[{"given":"Ioanna","family":"Deni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara H.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt E.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate J.","family":"Fairhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charisse Flerida A.","family":"Pasaje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heekuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella S.","family":"Bick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Kirkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehad","family":"Almaliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblle","family":"Duffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"O'Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catrin","family":"Uhlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquin C.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.A.","family":"da Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Gerwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bogyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fidock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2023.03.002_bib2","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in\u00a0vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2023.03.002_bib3","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"Uwimana","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","article-title":"High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine","volume":"225","author":"Straimer","year":"2022","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","article-title":"Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda","volume":"223","author":"Asua","year":"2021","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2023.03.002_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jsb.2006.01.005","article-title":"Diverse functions with a common regulator: ubiquitin takes command of an AAA ATPase","volume":"156","author":"Ye","year":"2006","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14728222.2019.1685981","article-title":"The proteasome as a target for protozoan parasites","volume":"23","author":"Xie","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.chembiol.2023.03.002_bib9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41467-021-21344-8","article-title":"20S proteasomes secreted by the malaria parasite promote its growth","volume":"12","author":"Dekel","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2023.03.002_bib10","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1128\/AAC.42.10.2731","article-title":"Proteasome inhibitors block development of Plasmodium spp","volume":"42","author":"Gantt","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2023.03.002_bib11","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/AAC.00088-09","article-title":"The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity","volume":"53","author":"Czesny","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2023.03.002_bib12","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1128\/AAC.00742-12","article-title":"Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors","volume":"57","author":"Tschan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2023.03.002_bib13","doi-asserted-by":"crossref","first-page":"E6863","DOI":"10.1073\/pnas.1806109115","article-title":"Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance","volume":"115","author":"Kirkman","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.03.002_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2023.03.002_bib15","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.03.002_bib16","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of Leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib17","doi-asserted-by":"crossref","first-page":"e0153521","DOI":"10.1128\/AAC.01535-21","article-title":"Identification of a proteasome-targeting arylsulfonamide with potential for the treatment of Chagas' disease","volume":"66","author":"Lima","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2023.03.002_bib18","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1021\/acs.jmedchem.2c00791","article-title":"Discovery of novel quinoline-based proteasome inhibitors for Human African Trypanosomiasis (HAT)","volume":"65","author":"Koester","year":"2022","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/cbic.201200007","article-title":"The carmaphycins: new proteasome inhibitors exhibiting an alpha,beta-epoxyketone warhead from a marine cyanobacterium","volume":"13","author":"Pereira","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.chembiol.2023.03.002_bib20","doi-asserted-by":"crossref","first-page":"13562","DOI":"10.1021\/ja507692y","article-title":"Identification of potent and selective non-covalent inhibitors of\u00a0the Plasmodium falciparum proteasome","volume":"136","author":"Li","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2023.03.002_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature16936","article-title":"Structure- and function-based design of Plasmodium-selective proteasome inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2023.03.002_bib22","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1021\/acs.jmedchem.7b00671","article-title":"Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity","volume":"60","author":"LaMonte","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib23","doi-asserted-by":"crossref","first-page":"11424","DOI":"10.1021\/jacs.8b06656","article-title":"Defining the determinants of specificity of Plasmodium proteasome inhibitors","volume":"140","author":"Yoo","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.chembiol.2023.03.002_bib24","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1021\/acs.jmedchem.9b00363","article-title":"Improvement of asparagine ethylenediamines as anti-malarial Plasmodium-selective proteasome inhibitors","volume":"62","author":"Zhan","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107213118","article-title":"Design of proteasome inhibitors with oral efficacy in\u00a0vivo against Plasmodium falciparum and selectivity over the human proteasome","volume":"118","author":"Xie","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.03.002_bib26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/acsinfecdis.1c00110","article-title":"High throughput screening to identify selective and nonpeptidomimetic proteasome inhibitors as antimalarials","volume":"7","author":"Mata-Cantero","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib27","doi-asserted-by":"crossref","first-page":"9279","DOI":"10.1002\/anie.202015845","article-title":"Development of a highly selective Plasmodium falciparum proteasome inhibitor with anti-malaria activity in humanized mice","volume":"60","author":"Zhan","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2023.03.002_bib28","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41564-019-0524-4","article-title":"The structure of the PA28-20S proteasome complex from Plasmodium falciparum and implications for proteostasis","volume":"4","author":"Xie","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib29","doi-asserted-by":"crossref","first-page":"e1007722","DOI":"10.1371\/journal.ppat.1007722","article-title":"Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in\u00a0vitro and synergize with multiple antimalarial agents","volume":"15","author":"Stokes","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2023.03.002_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel Plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib32","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciab716","article-title":"Efficacy of cipargamin (KAE609) in a randomized, phase II dose-escalation study in adults in Sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria","volume":"74","author":"Schmitt","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/acsinfecdis.8b00211","article-title":"Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in Plasmodium falciparum that confer in\u00a0vitro resistance to the clinical candidate DSM265","volume":"5","author":"White","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2023.03.002_bib35","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1038\/s41467-022-33403-9","article-title":"A G358S mutation in the Plasmodium falciparum Na(+) pump PfATP4 confers clinically-relevant resistance to cipargamin","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2023.03.002_bib36","doi-asserted-by":"crossref","first-page":"e1002132","DOI":"10.1371\/journal.pbio.1002132","article-title":"Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance","volume":"13","author":"Dogovski","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02312-20","article-title":"Plasmodium berghei K13 mutations mediate in\u00a0vivo artemisinin resistance that is reversed by proteasome inhibition","volume":"11","author":"Simwela","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.chembiol.2023.03.002_bib38","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1021\/acsinfecdis.0c00900","article-title":"A proteasome mutation sensitizes P.\u00a0falciparum Cam3.II K13(C580Y) parasites to DHA and OZ439","volume":"7","author":"Rosenthal","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib39","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.pt.2016.05.010","article-title":"Artemisinin action and resistance in Plasmodium falciparum","volume":"32","author":"Tilley","year":"2016","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib40","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/acsinfecdis.9b00527","article-title":"Plasmodium falciparum artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response","volume":"6","author":"Rosenthal","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trsl.2018.04.007","article-title":"The proteasome as a target to combat malaria: hits and misses","volume":"198","author":"Krishnan","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.chembiol.2023.03.002_bib42","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target validation and identification of novel boronate inhibitors of the Plasmodium falciparum proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib43","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1073\/pnas.94.13.6629","article-title":"Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors","volume":"94","author":"Bogyo","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.03.002_bib44","doi-asserted-by":"crossref","first-page":"e202203958","DOI":"10.1002\/chem.202203958","article-title":"Development of potent and highly selective epoxyketone-based Plasmodium proteasome inhibitors","author":"Almaliti","year":"2023","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.chembiol.2023.03.002_bib45","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1038\/cddis.2015.187","article-title":"FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing","volume":"6","author":"Wang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.chembiol.2023.03.002_bib46","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits\u00a0in\u00a0vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.03.002_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cbpa.2008.06.033","article-title":"Advances in and applications of proteasome inhibitors","volume":"12","author":"Moore","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1515\/hsz-2012-0212","article-title":"Covalent and non-covalent reversible proteasome inhibition","volume":"393","author":"Beck","year":"2012","journal-title":"Biol. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ja.2011.84","article-title":"Proteasome inhibitors mechanism; source for design of newer therapeutic agents","volume":"65","author":"Harer","year":"2012","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.chembiol.2023.03.002_bib50","doi-asserted-by":"crossref","first-page":"10727","DOI":"10.1038\/ncomms10727","article-title":"Synthetic RNA-protein modules integrated with native translation mechanisms to control gene expression in malaria parasites","volume":"7","author":"Ganesan","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2023.03.002_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.pt.2021.04.006","article-title":"Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials","volume":"37","author":"Duffey","year":"2021","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2023.03.002_bib54","doi-asserted-by":"crossref","first-page":"e0081722","DOI":"10.1128\/aac.00817-22","article-title":"Susceptibilities of Ugandan Plasmodium falciparum isolates to proteasome inhibitors","volume":"66","author":"Garg","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2023.03.002_bib55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41598-020-77644-4","article-title":"An integrated platform for genome engineering and gene expression perturbation in Plasmodium falciparum","volume":"11","author":"Nasamu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2023.03.002_bib56","doi-asserted-by":"crossref","first-page":"eabg6013","DOI":"10.1126\/scitranslmed.abg6013","article-title":"The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance","volume":"13","author":"Murithi","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2023.03.002_bib57","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1124\/mol.54.6.1140","article-title":"Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase","volume":"54","author":"Fidock","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib58","doi-asserted-by":"crossref","first-page":"e0116321","DOI":"10.1128\/AAC.01163-21","article-title":"Comparative analysis of Plasmodium falciparum genotyping via SNP detection, microsatellite profiling, and whole-genome sequencing","volume":"66","author":"Kanai","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2023.03.002_bib59","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/nar\/29.3.850","article-title":"Transformation of malaria parasites by the spontaneous uptake and expression of DNA from human erythrocytes","volume":"29","author":"Deitsch","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2023.03.002_bib60","doi-asserted-by":"crossref","first-page":"E1128","DOI":"10.1073\/pnas.1110574108","article-title":"Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion","volume":"108","author":"Xi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.03.002_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1107\/S0907444912001308","article-title":"Towards automated crystallographic structure refinement with phenix","volume":"68","author":"Afonine","year":"2012","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.chembiol.2023.03.002_bib62","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.chembiol.2014.04.010","article-title":"Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor","volume":"21","author":"Trivella","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2023.03.002_bib63","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib64","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.chembiol.2023.03.002_bib65","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.1260867","article-title":"K13-propeller mutations confer artemisinin resistance in Plasmodium falciparumclinical isolates","volume":"347","author":"Straimer","year":"2015","journal-title":"Science"}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945623000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945623000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:05:33Z","timestamp":1786219533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945623000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2451945623000612"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2023.03.002","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}